Taken together, the present study will be the first one to assess the efficacy and safety of pyrotinib plus nab-paclitaxel as adjuvant therapy in patients with T ≤ 3 cm, N0/N1mi, HER2 + breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.